Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -18934.67% is 142% below its 5-year average of -7813.46%, near the high end of its 5-year range (-557206.67%–-364.25%).
92.74% above its 12-month average of -260841.03%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -362368.18%.
EBITDA MARGIN
-18934.67%
EBITDA MARGIN AVG TTM
-260841.03%
EBITDA MARGIN AVG 3Y
-18226.57%
EBITDA MARGIN AVG 5Y
-7813.46%
EBITDA MARGIN AVG 10Y
-3307.90%
EBITDA MARGIN AVG 15Y
-2307.74%
EBITDA MARGIN AVG 20Y
-1592.90%
CURRENT VS TTM AVG
+92.74%
CURRENT VS 3Y AVG
-3.88%
CURRENT VS 5Y AVG
-142.33%
CURRENT VS 10Y AVG
-472.41%
CURRENT VS 15Y AVG
-720.49%
CURRENT VS 20Y AVG
-1088.69%
Celldex Therapeutics, Inc.
Market Cap
$2.17B
EBITDA Margin
-18934.67%
TTM Avg
-260841.03%
3Y Avg
-18226.57%
5Y Avg
-7813.46%
Market Cap
$2.11B
EBITDA Margin
10.90%
TTM Avg
10.48%
3Y Avg
9.90%
5Y Avg
9.38%
Market Cap
$2.06B
EBITDA Margin
39.14%
TTM Avg
19.43%
3Y Avg
-11.55%
5Y Avg
-189.29%
Market Cap
$2.05B
EBITDA Margin
7.12%
TTM Avg
6.21%
3Y Avg
-1.19%
5Y Avg
-11.55%
Market Cap
$2.31B
EBITDA Margin
26.92%
TTM Avg
28.50%
3Y Avg
31.74%
5Y Avg
29.80%
Market Cap
$2.02B
EBITDA Margin
-3042.18%
TTM Avg
-3200.65%
3Y Avg
-2392.49%
5Y Avg
-2392.49%
Market Cap
$2.02B
EBITDA Margin
40.34%
TTM Avg
23.31%
3Y Avg
-20.04%
5Y Avg
-112.62%
Market Cap
$2.01B
EBITDA Margin
1.74%
TTM Avg
-0.52%
3Y Avg
3.36%
5Y Avg
2.51%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | $2.17B | -18934.67% | -260841.03% | -18226.57% | -7813.46% |
| Addus HomeCare Corporation (ADUS)vs › | $2.11B | 10.90% | 10.48% | 9.90% | 9.38% |
| Alvotech (ALVO)vs › | $2.07B | 19.79% | 20.20% | -178.47% | -247.76% |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.06B | 39.14% | 19.43% | -11.55% | -189.29% |
| Inspire Medical Systems, Inc. (INSP)vs › | $2.05B | 7.12% | 6.21% | -1.19% | -11.55% |
| Harmony Biosciences Holdings, Inc. (HRMY)vs › | $2.31B | 26.92% | 28.50% | 31.74% | 29.80% |
| Immunome, Inc. (IMNM)vs › | $2.02B | -3042.18% | -3200.65% | -2392.49% | -2392.49% |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $2.02B | 40.34% | 23.31% | -20.04% | -112.62% |
| Fortrea Holdings Inc. (FTRE)vs › | $2.01B | 1.74% | -0.52% | 3.36% | 2.51% |
| AxoGen, Inc. (AXGN)vs › | $2.00B | 0.15% | 1.29% | -6.34% | -9.86% |
Gross Margin
100.0%
EBITDA Margin
-18934.7%
Operating Margin
-19160.0%
Net Margin
-268385.7%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -362368.18% |
| 2026-03-31 | -557206.67% |
| 2025-12-31 | -115161.33% |
| 2025-06-30 | -8627.95% |
| 2025-03-31 | -8902.45% |
| 2024-12-31 | -4698.55% |
| 2024-09-30 | -1608.90% |
| 2024-06-30 | -1822.26% |
| 2024-03-31 | -25533.97% |
| 2023-12-31 | -1134.54% |
| 2023-09-30 | -2667.90% |
| 2023-06-30 | -12107.84% |
| 2023-03-31 | -3282.83% |
| 2022-12-31 | -1687.04% |
| 2022-09-30 | -6640.05% |
| 2022-06-30 | -21874.23% |
| 2022-03-31 | -12900.00% |
| 2021-12-31 | -5857.19% |
| 2021-09-30 | -13118.95% |
| 2021-06-30 | -364.25% |
| 2021-03-31 | -2315.91% |
| 2020-12-31 | -634.77% |
| 2020-09-30 | -2018.11% |
| 2020-06-30 | -4329.24% |
| 2020-03-31 | -428.96% |
| 2019-12-31 | -1335.29% |
| 2019-09-30 | -1947.99% |
| 2019-06-30 | -1553.01% |
| 2019-03-31 | -1164.14% |
| 2018-12-31 | -646.32% |
| 2018-09-30 | -736.34% |
| 2018-06-30 | -574.74% |
| 2018-03-31 | -2911.14% |
| 2017-12-31 | -702.55% |
| 2017-09-30 | -782.67% |
| 2017-06-30 | -723.50% |
| 2017-03-31 | -2185.27% |
| 2016-12-31 | -1795.89% |
| 2016-09-30 | -1308.06% |
| 2016-06-30 | -2262.06% |
| 2016-03-31 | -2663.78% |
| 2015-12-31 | -1806.59% |
| 2015-09-30 | -3055.65% |
| 2015-06-30 | -1459.32% |
| 2015-03-31 | -6184.36% |
| 2014-12-31 | -2110.63% |
| 2014-09-30 | -2678.11% |
| 2014-06-30 | -4681.25% |
| 2014-03-31 | -7369.47% |
| 2013-12-31 | -3443.71% |
| 2013-09-30 | -2299.69% |
| 2013-06-30 | -18483.51% |
| 2013-03-31 | -690.97% |
| 2012-12-31 | -433.92% |
| 2012-09-30 | -449.57% |
| 2012-06-30 | -630.51% |
| 2012-03-31 | -511.84% |
| 2011-12-31 | 1311.01% |
| 2011-09-30 | -434.02% |
| 2011-06-30 | -452.36% |
| 2011-03-31 | -342.33% |
| 2010-12-31 | 75.78% |
| 2010-09-30 | -324.63% |
| 2010-06-30 | -268.65% |
| 2010-03-31 | -187.96% |
| 2009-12-31 | 527.28% |
| 2009-09-30 | -159.85% |
| 2009-06-30 | -297.09% |
| 2009-03-31 | -187.73% |
| 2008-12-31 | 406.88% |
| 2008-09-30 | -329.27% |
| 2008-06-30 | -486.72% |
| 2008-03-31 | -14772.87% |
| 2007-12-31 | -271.00% |
| 2007-09-30 | -1292.26% |
| 2007-06-30 | -179.57% |
| 2007-03-31 | -337.85% |
| 2006-12-31 | -1691.10% |
| 2006-09-30 | -1652.70% |
| 2006-06-30 | -1154.18% |
| 2006-03-31 | -64.92% |
| 2005-12-31 | 2398.13% |
| 2005-09-30 | -483.00% |
| 2005-06-30 | -677.51% |
| 2005-03-31 | -481.92% |
| 2004-12-31 | -138.91% |
| 2004-09-30 | -644.71% |
| 2004-06-30 | -400.77% |
| 2004-03-31 | -50.87% |
| 2003-12-31 | -314.74% |
| 2003-09-30 | -85.24% |
| 2003-06-30 | -254.14% |
| 2003-03-31 | -447.29% |
| 2002-12-31 | -394.12% |
| 2002-09-30 | -0.01% |
